These findings pave the way for the future use of miR-135b–BMAL1–YY1 signalling as a predictive biomarker for PC inception and progression, as a prognostic factor for patient survival outcome, and as a therapeutic target for the modulation of GEM sensitivity. This evidence concerns the gene BMAL1 and pachyonychia congenita.